Resultados da pesquisa - David M. Gershenson

Refinar resultados
  1. 1
    Update on malignant ovarian germ cell tumors

    Update on malignant ovarian germ cell tumors Por David M. Gershenson

    Publicado em 1993
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Fertility-Sparing Surgery for Malignancies in Women

    Fertility-Sparing Surgery for Malignancies in Women Por David M. Gershenson

    Publicado em 2005
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    Low-grade serous carcinoma of the ovary or peritoneum

    Low-grade serous carcinoma of the ovary or peritoneum Por David M. Gershenson

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  4. 4
    Sexual dysfunction and treatment for early stage cervical cancer

    Sexual dysfunction and treatment for early stage cervical cancer Por Leslie R. Schover, Michael Fife, David M. Gershenson

    Publicado em 1989
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum

    Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum Por David M. Gershenson, Charlotte C. Sun, Kwong‐Kwok Wong

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Unmasking the complexities of mucinous ovarian carcinoma

    Unmasking the complexities of mucinous ovarian carcinoma Por Michael Frumovitz, Kathleen M. Schmeler, Anaís Malpica, Anil K. Sood, David M. Gershenson

    Publicado em 2010
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  7. 7
    Trends of low-grade serous ovarian carcinoma in the United States

    Trends of low-grade serous ovarian carcinoma in the United States Por Koji Matsuo, Hiroko Machida, Brendan H. Grubbs, Anil K. Sood, David M. Gershenson

    Publicado em 2017
    Obter o texto integral
    Carta
    Adic. favoritos
    Na minha lista:
  8. 8
    Serous borderline tumors of the ovary with noninvasive peritoneal implants

    Serous borderline tumors of the ovary with noninvasive peritoneal implants Por David M. Gershenson, Elvio G. Silva, Guillermo Tortolero‐Luna, Charles Levenback, Mitchell Morris, Carmen Tornos

    Publicado em 1998
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors

    The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors Por Jubilee Brown, Hyun S. Shvartsman, Michael T. Deavers, Thomas W. Burke, Mark F. Munsell, David M. Gershenson

    Publicado em 2004
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    MEK inhibitor resistance mechanisms and recent developments in combination trials

    MEK inhibitor resistance mechanisms and recent developments in combination trials Por Eucharist Kun, Yvonne T.M. Tsang, Chun Wai Ng, David M. Gershenson, Kwong‐Kwok Wong

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  11. 11
    The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

    The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer Por Erin K. Crane, Charlotte C. Sun, Pedro T. Ramírez, Kathleen M. Schmeler, Anaís Malpica, David M. Gershenson

    Publicado em 2014
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)

    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001) Por Panagiotis A. Konstantinopoulos, William E. Brady, John Farley, Amy E. Armstrong, Denise Uyar, David M. Gershenson

    Publicado em 2018
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    Ovarian serous borderline tumors with invasive peritoneal implants

    Ovarian serous borderline tumors with invasive peritoneal implants Por David M. Gershenson, Elvio G. Silva, Lawrence B. Levy, Thomas W. Burke, Judith K. Wolf, Carmen Tornos

    Publicado em 1998
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    The current status of surgical staging of ovarian serous borderline tumors

    The current status of surgical staging of ovarian serous borderline tumors Por Paul Lin, David M. Gershenson, Michael W. Bevers, Kristin R. Lucas, Thomas W. Burke, Elvio G. Silva

    Publicado em 1999
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience

    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience Por Heather J. Dalton, Nicole D. Fleming, Charlotte C. Sun, Priya Bhosale, Kathleen M. Schmeler, David M. Gershenson

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum

    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum Por David M. Gershenson, Diane C. Bodurka, Robert L. Coleman, Karen H. Lu, Anaís Malpica, Charlotte C. Sun

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Subcellular Localization of p27kip1 Expression Predicts Poor Prognosis in Human Ovarian Cancer

    Subcellular Localization of p27kip1 Expression Predicts Poor Prognosis in Human Ovarian Cancer Por Daniel Rosen, Gong Yang, Kathy Q. Cai, Robert C. Bast, David M. Gershenson, Elvio G. Silva, Jinsong Liu

    Publicado em 2005
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Prognosis of surgically determined complete responders in advanced ovarian cancer

    Prognosis of surgically determined complete responders in advanced ovarian cancer Por David M. Gershenson, Larry J. Copeland, Taylor Wharton, E. Neely Atkinson, Nour Sneige, Creighton L. Edwards, Felix N. Rutledge

    Publicado em 1985
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Survival in Women With Grade 1 Serous Ovarian Carcinoma

    Survival in Women With Grade 1 Serous Ovarian Carcinoma Por Amanda N. Fader, James Java, Stefanie Ueda, Robert E. Bristow, Deborah K. Armstrong, Michael A. Bookman, David M. Gershenson

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells

    ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells Por Tsz-Lun Yeung, Cecilia S. Leung, Kwong‐Kwok Wong, Arthur Gutierrez‐Hartmann, Joseph Kwong, David M. Gershenson, Samuel C. Mok

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: